Related Experiment Video
Updated: Jun 13, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Achieving equitable, timely and comprehensive biomarker testing for patients with NSCLC.
Neal Navani1, Anna Sharman2, Matthew Evison3
1Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK; Department of Thoracic Medicine, University College London Hospital, London, UK.
Comprehensive biomarker analysis for non-small cell lung cancer (NSCLC) is crucial. Implementing best practices for molecular profiling ensures timely and equitable treatment for all NSCLC patients in the UK.
Area of Science:
- Oncology
- Molecular Pathology
- Genomics
Background:
- Non-small cell lung cancer (NSCLC) diagnosis and treatment rely heavily on accurate biomarker analysis.
- Current biomarker testing in the UK faces complexities and challenges impacting timely and comprehensive patient care.
More Related Videos
10:35A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
Published on: April 5, 2018
08:49Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
Published on: May 27, 2016